Genetic Variation in Melatonin Pathway Enzymes in Children with Autism Spectrum Disorder and Comorbid Sleep Onset Delay

Journal of Autism and Developmental Disorders

Volumn 45, Issue 1, 2015, Pages 100-110

  Veatch, Olivia J ^a   Pendergast, Julie S ^a   Allen, Melissa J ^b   Leu, Roberta M ^c   Johnson, Carl Hirschie ^a   Elsea, Sarah H ^d   Malow, Beth A ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Biomarkers; Comorbidities; Endophenotypes; Genetic analyses; Phenotypic subgroups; Phenotyping

Indexed keywords

ACETYLSEROTONIN METHYLTRANSFERASE; CYP1A2 PROTEIN, HUMAN; CYTOCHROME P450 1A2; MELATONIN;

AUTISM; BIOSYNTHESIS; CHILD; CLINICAL TRIAL (TOPIC); COMPLICATION; DNA MUTATIONAL ANALYSIS; ENDOPHENOTYPE; ENZYMOLOGY; GENETICS; GENOTYPE; HUMAN; INSOMNIA; MALE; MUTATION; PRESCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM;

ACETYLSEROTONIN O-METHYLTRANSFERASE; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; CYTOCHROME P-450 CYP1A2; DNA MUTATIONAL ANALYSIS; ENDOPHENOTYPES; GENOTYPE; HUMANS; MALE; MELATONIN; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 84939877132     PISSN: 01623257     EISSN: 15733432     Source Type: Journal    
DOI: 10.1007/s10803-014-2197-4     Document Type: Article

References (64)

1. Abnet, C. C., Fagundes, R. B., Strickland, P. T., Kamangar, F., Roth, M. J., Taylor, P. R., et al. (2007). The influence of genetic polymorphisms in Ahr, CYP1A1, CYP1A2, CYP1B1, GST M1, GST T1 and UGT1A1 on urine 1-hydroxypyrene glucuronide concentrations in healthy subjects from Rio Grande do Sul, Brazil. Carcinogenesis,28, 112–117.
2. Ackermann, K., & Stehle, J. H. (2006). Melatonin synthesis in the human pineal gland: Advantages, implications, and difficulties. Chronobiology International,23, 369–379.
3. Aklillu, E., Carrillo, J. A., Makonnen, E., Hellman, K., Pitarque, M., Bertilsson, L., et al. (2003). Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: Characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. Molecular Pharmacology,64, 659–669.
4. Alarcon, M., Abrahams, B. S., Stone, J. L., Duvall, J. A., Perederiy, J. V., Bomar, J. M., et al. (2008). Linkage, association, and gene-expression analyses identify CNTNAP2 as an autism-susceptibility gene. American Journal of Human Genetics,82, 150–159.
5. Alarcon, M., Yonan, A. L., Gilliam, T. C., Cantor, R. M., & Geschwind, D. H. (2005). Quantitative genome scan and Ordered-Subsets Analysis of autism endophenotypes support language QTLs. Molecular Psychiatry,10, 747–757.
6. American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders, 4th edition, text revision. Washington DC: American Psychiatric Association.
7. American Psychiatric Association. (2013). Report of DSM-5 Proposed Criteria for Autism Spectrum Disorder Designed to Provide More Accurate Diagnosis and Treatment. Arlington, VA: American Psychiatric Association.
8. Arendt, J. (1998). Melatonin and the pineal gland: Influence on mammalian seasonal and circadian physiology. Reviews of Reproduction,3, 13–22.
9. Arendt, J., Bojkowski, C., Franey, C., Wright, J., & Marks, V. (1985). Immunoassay of 6-hydroxymelatonin sulfate in human plasma and urine: Abolition of the urinary 24-hour rhythm with atenolol. Journal of Clinical Endocrinology and Metabolism,60, 1166–1173.
10. Bailey, A., Le, C. A., Gottesman, I., Bolton, P., Simonoff, E., Yuzda, E., et al. (1995). Autism as a strongly genetic disorder: Evidence from a British twin study. Psychological Medicine,25, 63–77.
11. Barrett, J. C., Fry, B., Maller, J., & Daly, M. J. (2005). Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics,21, 263–265.
12. Botros, H. G., Legrand, P., Pagan, C., Bondet, V., Weber, P., Ben-Abdallah, M., et al. (2012). Crystal structure and functional mapping of human ASMT, the last enzyme of the melatonin synthesis pathway. Journal of Pineal Research,54, 46.
13. Braam, W., Keijzer, H., Struijker, B. H., Didden, R., Smits, M., & Curfs, L. (2013). CYP1A2 polymorphisms in slow melatonin metabolisers: A possible relationship with autism spectrum disorder? Journal of Intellectual Disability Research,57, 993–1000.
14. Braam, W., Van Geijlswijk, I., Keijzer, H., Smits, M. G., Didden, R., & Curfs, L. M. (2010). Loss of response to melatonin treatment is associated with slow melatonin metabolism. Journal of Intellectual Disability Research,54, 547–555.
15. Bruining, H., De Sonneville, L., Swaab, H., De Jonge, M., Kas, M., van Engeland, H., et al. (2010). Dissecting the clinical heterogeneity of autism spectrum disorders through defined genotypes. PLoS ONE,5, e10887.
16. Cai, G., Edelmann, L., Goldsmith, J. E., Cohen, N., Nakamine, A., Reichert, J. G., et al. (2008). Multiplex ligation-dependent probe amplification for genetic screening in autism spectrum disorders: Efficient identification of known microduplications and identification of a novel microduplication in ASMT. BMC Medical Genomics,1, 50.
17. Cook, E. H, Jr. (2001). Genetics of autism. Child and Adolescent Psychiatric Clinics of North America,10, 333–350.
18. Couturier, J. L., Speechley, K. N., Steele, M., Norman, R., Stringer, B., & Nicolson, R. (2005). Parental perception of sleep problems in children of normal intelligence with pervasive developmental disorders: Prevalence, severity, and pattern. Journal of the American Academy of Child and Adolescent Psychiatry,44, 815–822.
19. Dauvilliers, Y., Morin, C., Cervena, K., Carlander, B., Touchon, J., Besset, A., et al. (2005). Family studies in insomnia. Journal of Psychosomatic Research,58, 271–278.
20. Djordjevic, N., Ghotbi, R., Bertilsson, L., Jankovic, S., & Aklillu, E. (2008). Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes. European Journal of Clinical Pharmacology,64, 381–385.
21. Eap, C. B., Bender, S., Jaquenoud, S. E., Cucchia, G., Jonzier-Perey, M., Baumann, P., et al. (2004). Nonresponse to clozapine and ultrarapid CYP1A2 activity: Clinical data and analysis of CYP1A2 gene. Journal of Clinical Psychopharmacology,24, 214–219.
22. Galecki, P., Szemraj, J., Bartosz, G., Bienkiewicz, M., Galecka, E., Florkowski, A., et al. (2010). Single-nucleotide polymorphisms and mRNA expression for melatonin synthesis rate-limiting enzyme in recurrent depressive disorder. Journal of Pineal Research,48, 311–317.
23. Gehrman, P. R., Meltzer, L. J., Moore, M., Pack, A. I., Perlis, M. L., Eaves, L. J., et al. (2011). Heritability of insomnia symptoms in youth and their relationship to depression and anxiety. Sleep,34, 1641–1646.
24. Geschwind, D. H. (2011). Genetics of autism spectrum disorders. Trends in Cognitive Sciences,15, 409–416.
25. Ghotbi, R., Christensen, M., Roh, H. K., Ingelman-Sundberg, M., Aklillu, E., & Bertilsson, L. (2007). Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. European Journal of Clinical Pharmacology,63, 537–546.
26. Goldman SE, Adkins KW, Calcutt MW, Carter MD, Goodpaster RL, Wang L et al (2014) Melatonin in Children with Autism Spectrum Disorders: Endogenous and Pharmacokinetic Profiles in Relation to Sleep. J Autism Dev Disord.
27. Goldman, S. E., Surdyka, K., Cuevas, R., Adkins, K., Wang, L., & Malow, B. A. (2009). Defining the sleep phenotype in children with autism. Developmental Neuropsychology,34, 560–573.
28. Gottesman, I. I., & Gould, T. D. (2003). The endophenotype concept in psychiatry: Etymology and strategic intentions. American Journal of Psychiatry,160, 636–645.
29. Hallmayer, J., Cleveland, S., Torres, A., Phillips, J., Cohen, B., Torigoe, T., et al. (2011). Genetic heritability and shared environmental factors among twin pairs with autism. Archives of General Psychiatry,68, 1095–1102.
30. Heath, A. C., Kendler, K. S., Eaves, L. J., & Martin, N. G. (1990). Evidence for genetic influences on sleep disturbance and sleep pattern in twins. Sleep,13, 318–335.
31. Hu, V. W., Addington, A., & Hyman, A. (2011). Novel autism subtype-dependent genetic variants are revealed by quantitative trait and subphenotype association analyses of published GWAS data. PLoS ONE,6, e19067.
32. Hu, V. W., Sarachana, T., Kim, K. S., Nguyen, A., Kulkarni, S., Steinberg, M. E., et al. (2009). Gene expression profiling differentiates autism case–controls and phenotypic variants of autism spectrum disorders: Evidence for circadian rhythm dysfunction in severe autism. Autism Research,2, 78–97.
33. Irish, L. A., Kline, C. E., Rothenberger, S. D., Krafty, R. T., Buysse, D. J., Kravitz, H. M., et al. (2013). A 24-hour approach to the study of health behaviors: Temporal relationships between waking health behaviors and sleep. Annals of Behavioral Medicine,47, 189.
34. Jonsson, L., Ljunggren, E., Bremer, A., Pedersen, C., Landen, M., Thuresson, K., et al. (2010). Mutation screening of melatonin-related genes in patients with autism spectrum disorders. BMC Medical Genomics,3, 10.
35. Klepstad, P., Dale, O., Skorpen, F., Borchgrevink, P. C., & Kaasa, S. (2005). Genetic variability and clinical efficacy of morphine. Acta Anaesthesiologica Scandinavica,49, 902–908.
36. Krakowiak, P., Goodlin-Jones, B., Hertz-Picciotto, I., Croen, L. A., & Hansen, R. L. (2008). Sleep problems in children with autism spectrum disorders, developmental delays, and typical development: A population-based study. Journal of Sleep Research,17, 197–206.
37. Kuo, H. W., Liu, S. C., Tsou, H. H., Liu, S. W., Lin, K. M., Lu, S. C., et al. (2013). CYP1A2 genetic polymorphisms are associated with early antidepressant escitalopram metabolism and adverse reactions. Pharmacogenomics,14, 1191–1201.
38. Laika, B., Leucht, S., Heres, S., Schneider, H., & Steimer, W. (2010). Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome. The Pharmacogenomics Journal,10, 20–29.
39. Leyfer, O. T., Folstein, S. E., Bacalman, S., Davis, N. O., Dinh, E., Morgan, J., et al. (2006). Comorbid psychiatric disorders in children with autism: Interview development and rates of disorders. Journal of Autism and Developmental Disorders,36, 849–861.
40. Lin, K. M., Tsou, H. H., Tsai, I. J., Hsiao, M. C., Hsiao, C. F., Liu, C. Y., et al. (2010). CYP1A2 genetic polymorphisms are associated with treatment response to the antidepressant paroxetine. Pharmacogenomics,11, 1535–1543.
41. Llerena, A., Berecz, R., Penas-Lledo, E., Suveges, A., & Farinas, H. (2013). Pharmacogenetics of clinical response to risperidone. Pharmacogenomics,14, 177–194.
42. Lodato, F., Araujo, J., Barros, H., Lopes, C., Agodi, A., Barchitta, M., et al. (2013). Caffeine intake reduces sleep duration in adolescents. Nutrition Research,33, 726–732.
43. Lohsoonthorn, V., Khidir, H., Casillas, G., Lertmaharit, S., Tadesse, M. G., Pensuksan, W. C., et al. (2013). Sleep quality and sleep patterns in relation to consumption of energy drinks, caffeinated beverages, and other stimulants among Thai college students. Sleep Breath,17, 1017–1028.
44. Lord, C., Rutter, M., Goode, S., Heemsbergen, J., Jordan, H., Mawhood, L., et al. (1989). Autism diagnostic observation schedule: A standardized observation of communicative and social behavior. Journal of Autism and Developmental Disorders,19, 185–212.
45. Malow, B., Adkins, K. W., McGrew, S. G., Wang, L., Goldman, S. E., Fawkes, D., et al. (2012). Melatonin for sleep in children with autism: A controlled trial examining dose, tolerability, and outcomes. Journal of Autism and Developmental Disorders,42, 1729–1737.
46. Malow BA, Adkins KW, Reynolds A, Weiss SK, Loh A, Fawkes D, et al (2013): Parent-Based Sleep Education for Children with Autism Spectrum Disorders. J Autism Dev Disord.
47. Masana, M. I., & Dubocovich, M. L. (2001). Melatonin receptor signaling: Finding the path through the dark. Science STKE,2001, e39.
48. Melke, J., Goubran, B. H., Chaste, P., Betancur, C., Nygren, G., Anckarsater, H., et al. (2008). Abnormal melatonin synthesis in autism spectrum disorders. Molecular Psychiatry,13, 90–98.
49. Ozdemir, V., Kalow, W., Okey, A. B., Lam, M. S., Albers, L. J., Reist, C., et al. (2001). Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C–>A polymorphism in intron 1 of the CYP1A2 gene: Effect of grapefruit juice and low-dose fluvoxamine. Journal of Clinical Psychopharmacology,21, 603–607.
50. Persico, A. M., & Bourgeron, T. (2006). Searching for ways out of the autism maze: Genetic, epigenetic and environmental clues. Trends in Neurosciences,29, 349–358.
51. Peter, B., Raskind, W. H., Matsushita, M., Lisowski, M., Vu, T., Berninger, V. W., et al. (2011). Replication of CNTNAP2 association with nonword repetition and support for FOXP2 association with timed reading and motor activities in a dyslexia family sample. Journal of Neurodevelopmental Disorders,3, 39–49.
52. Roses, A. D., Saunders, A. M., Huang, Y., Strum, J., Weisgraber, K. H., & Mahley, R. W. (2007). Complex disease-associated pharmacogenetics: Drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer’s disease). The Pharmacogenomics Journal,7, 10–28.
53. Rossignol, D. A., & Frye, R. E. (2011). Melatonin in autism spectrum disorders: A systematic review and meta-analysis. Developmental Medicine and Child Neurology,53, 783–792.
54. Sachse, C., Bhambra, U., Smith, G., Lightfoot, T. J., Barrett, J. H., Scollay, J., et al. (2003). Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: Allele frequencies, linkage disequilibrium and influence on caffeine metabolism. British Journal of Clinical Pharmacology,55, 68–76.
55. Sachse, C., Brockmoller, J., Bauer, S., & Roots, I. (1999). Functional significance of a C–>A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. British Journal of Clinical Pharmacology,47, 445–449.
56. Souders, M. C., Mason, T. B., Valladares, O., Bucan, M., Levy, S. E., Mandell, D. S., et al. (2009). Sleep behaviors and sleep quality in children with autism spectrum disorders. Sleep,32, 1566–1578.
57. Statacorp. (2009). Stata Statistical Software. College Station, TX: Statacorp LP.
58. Talebizadeh, Z., Arking, D., & Hu, V. (2013). A novel stratification method in linkage studies to address inter- and intra-family heterogeneity in autism. PLoS Genetics,8, e67569.
59. Thorn, C. F., Aklillu, E., Klein, T. E., & Altman, R. B. (2012). PharmGKB summary: Very important pharmacogene information for CYP1A2. Pharmacogenetics and Genomics,22, 73–77.
60. Toma, C., Rossi, M., Sousa, I., Blasi, F., Bacchelli, E., Alen, R., et al. (2007). Is ASMT a susceptibility gene for autism spectrum disorders? A replication study in European populations. Molecular Psychiatry,12, 977–979.
61. Veatch, O. J., & Haines, J. L. (2013). Evaluating small molecule effects on expression of ASMT. Nashville: Vanderbilt University.
62. Wang, L., Li, J., Ruan, Y., Lu, T., Liu, C., Jia, M., et al. (2013). Sequencing ASMT identifies rare mutations in Chinese Han patients with autism. PLoS ONE,8, e53727.
63. Watson, N. F., Goldberg, J., Arguelles, L., & Buchwald, D. (2006). Genetic and environmental influences on insomnia, daytime sleepiness, and obesity in twins. Sleep,29, 645–649.
64. Whitehouse, A. J., Bishop, D. V., Ang, Q. W., Pennell, C. E., & Fisher, S. E. (2011). CNTNAP2 variants affect early language development in the general population. Genes, Brain and Behavior,10, 451–456.